Melatonin
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Melatonin is not a sedative. That distinction matters. It is a chronobiotic – a molecule whose primary function is to communicate temporal information from the suprachiasmatic nucleus to peripheral tissues. Synthesized from serotonin in the pineal gland under conditions of darkness, it rises in the evening, peaks between 02:00 and 04:00, and recedes before dawn. What follows is a description of the receptor architecture through which that signal propagates.
MT1 receptor signaling initiates the acute circadian message of biological night. MT1 agonism suppresses SCN neuronal firing through high-affinity Gi-coupled receptor activation and helps explain how melatonin can advance or delay circadian phase depending on timing.
MT2 receptor signaling shapes phase shifting at the margins of the light dark cycle. MT2 agonism mediates responses at light-dark transitions and also modulates insulin secretion in pancreatic beta cells, with MTNR1B variants linking this receptor to elevated fasting glucose and type 2 diabetes risk.
Nuclear receptor effects extend melatonin biology beyond rapid membrane signaling. Binding at RORα and RZRβ influences transcription of core clock genes such as BMAL1, CLOCK, PER, and CRY, providing context for immunomodulatory and anti-inflammatory effects observed outside acute sleep induction.
Antioxidant cascade chemistry distinguishes melatonin from many redox-active molecules. Melatonin and its metabolites participate in sequential one-way antioxidant reactions without redox cycling, and mitochondrial concentrations exceed plasma levels, suggesting preferential activity at sites of high oxidative load.
What we observe
What people notice in sleep and timing
Sleep-onset latency reduction and circadian phase-shifting are among the most robustly documented effects in human chronobiology. Antioxidant and immunomodulatory effects are well-characterized in vitro, with human data still accumulating. Individual response varies with endogenous melatonin status, timing of administration, and dose.
01
Sleep-Onset Latency
02
Circadian Phase Advancement
03
Mitochondrial Antioxidant Activity
04
Immune Modulation
05
Neuroprotection
06
Intraocular Pressure Regulation
Evidence
What research shows on melatonin
The studies below represent a cross-section of published evidence, chosen to illustrate the range of contexts in which melatonin has been examined. They are not exhaustive, and inclusion does not constitute endorsement of any particular application. The literature is offered as a map, not a prescription.
Exogenous melatonin for delayed circadian phase: a systematic review and meta-analysis of randomized controlled trials
Pooled analysis of 18 randomized controlled trials found that melatonin administered 4–6 hours before DLMO produced statistically significant phase advances in adults with delayed sleep-wake phase disorder. Low doses (0.5–1 mg) were as effective as higher doses for phase-shifting, with fewer reports of morning grogginess. Sleep-onset latency was reduced by a mean of 23 minutes across included studies.
Melatonin as a mitochondrial protector: evidence from ischemia-reperfusion models and implications for human aging
A comprehensive review of 47 preclinical studies documented consistent attenuation of mitochondrial oxidative stress following melatonin administration in ischemia-reperfusion models across cardiac, hepatic, and neural tissues. Melatonin concentrations in mitochondria were measured at 10- to 100-fold higher than concurrent plasma levels, supporting the hypothesis of active mitochondrial uptake. Authors noted the absence of large-scale human trials as a significant gap in the literature.
MTNR1B variant rs10830963 and fasting glucose: a Mendelian randomization study in 94,000 European adults
Mendelian randomization analysis using data from the UK Biobank and EPIC-Norfolk cohort found that carriers of the MTNR1B risk allele (rs10830963) had significantly elevated fasting plasma glucose and a 19% higher odds of type 2 diabetes diagnosis compared to non-carriers, independent of BMI and sleep duration. Findings support a causal role for melatonin receptor signaling in pancreatic beta-cell function and glucose homeostasis.
From lyophilized powder to a usable solution.
Peptide
Typically 0.5 mg, 1 mg, 3 mg, or 5 mg per unit (tablet/capsule); liquid preparations at 1 mg/mL
Diluent
No reconstitution required for standard oral/sublingual forms
Final concentration
0.5–10 mg per dose unit depending on formulation and intended application
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Melatonin’s efficacy is inseparable from timing; dose and circadian phase interact to produce different, sometimes opposite, effects. The framework below reflects patterns observed in the chronobiological literature and is not a prescription.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store in a cool, dark environment below 25°C; melatonin degrades with prolonged light and heat exposure.
- Keep in original opaque or amber packaging; avoid transparent containers under fluorescent lighting.
- Shelf life typically 24–36 months from manufacture date when stored correctly; verify certificate of analysis for potency.
- Liquid preparations should be refrigerated after opening and used within 60 days; check manufacturer guidance.
- Do not freeze sublingual or liquid formulations; freezing may alter dissolution characteristics and bioavailability.
Side effects
What members describe
- Morning grogginess or sleep inertia - most commonly reported with doses above 3 mg or with administration too close to wake time.
- Headache - reported in a minority of users, typically at higher doses; often resolves with dose reduction.
- Vivid dreams or altered dream architecture - consistent with melatonin's influence on REM sleep timing and density.
- Hypothermia - melatonin lowers core body temperature as part of its sleep-initiation mechanism; rarely clinically significant at standard doses.
- Potential suppression of endogenous melatonin synthesis with chronic high-dose use - theoretical concern supported by receptor desensitization data; clinical significance in humans not fully established.
Contradictions
Reasons to abstain
- Autoimmune conditions - melatonin's immunostimulatory effects at higher doses may theoretically exacerbate autoimmune activity; use with caution and physician oversight.
- Concurrent anticoagulant therapy (e.g., warfarin) - case reports and pharmacodynamic data suggest possible potentiation of anticoagulant effect; monitor INR if co-administered.
- MTNR1B risk-allele carriers with impaired fasting glucose - given genetic evidence linking MT2 signaling to beta-cell function, high-dose nocturnal melatonin warrants metabolic monitoring in this population.
- Pregnancy and lactation - melatonin crosses the placenta and is present in breast milk; safety data in human pregnancy are insufficient; avoid without specialist guidance.
- Children and adolescents - endogenous melatonin systems are still developing; exogenous supplementation in pediatric populations should be supervised by a qualified clinician.
Synergies
Melatonin stacks for sleep goals
Melatonin occupies a foundational position in any circadian-aware protocol. Its interactions with other signaling molecules are well-described in the literature – some synergistic, some requiring careful sequencing. The following pairings reflect patterns observed in research contexts. They are not prescriptions. Aeterna does not prescribe, dispense, or sell.
FAQ
Your questions, patiently answered
The distinction is meaningful. Melatonin does not induce sleep directly – it signals darkness and biological night to the brain and peripheral tissues. In individuals with normal circadian alignment, this signal facilitates sleep onset. In those with circadian misalignment, it can re-entrain the clock. Calling it a sleep hormone is a simplification that has led to widespread misuse – particularly the reflexive use of high doses as a sedative substitute.
A 2023 analysis published in the Journal of Clinical Sleep Medicine found that many OTC melatonin products contain between 83% and 478% of their labeled dose. Separately, the chronobiological literature consistently shows that 0.5 mg is as effective as 5 mg for phase-shifting, and that higher doses do not proportionally improve sleep-onset outcomes. The discrepancy between commercial dosing and research dosing reflects market convention more than pharmacological rationale.
The evidence is mixed. Short-term use at physiological doses (0.5–1 mg) does not appear to meaningfully suppress endogenous synthesis. Chronic high-dose use raises theoretical concerns about receptor desensitization and feedback suppression of pineal output, but robust long-term human data are limited. This remains an open question in the literature – one worth weighing when considering chronic supplementation protocols.
Dim-light melatonin onset (DLMO) is the point in the evening when salivary or plasma melatonin rises above a defined threshold – typically 3–4 pg/mL in saliva – under conditions of dim light. It is the most reliable marker of individual circadian phase. Administering melatonin 4–6 hours before DLMO produces phase advancement; administration near or after DLMO has minimal phase-shifting effect. Without knowing DLMO, timing decisions are approximations.
The MTNR1B literature suggests there is. The rs10830963 risk variant in the melatonin receptor gene is associated with elevated fasting glucose and increased type 2 diabetes risk in large population studies. Separately, circadian disruption – which impairs endogenous melatonin rhythmicity – is independently associated with metabolic dysregulation. Whether exogenous melatonin supplementation improves metabolic outcomes in at-risk populations is an active area of investigation.
Prescription hypnotics – benzodiazepines, Z-drugs, and orexin antagonists – act primarily on GABA-A receptors or orexin receptors to suppress arousal. Melatonin acts on MT1 and MT2 receptors to signal circadian phase. The former suppress the nervous system; the latter inform it. This distinction has clinical implications: melatonin does not produce the tolerance, dependence, or rebound insomnia associated with GABAergic hypnotics, and its effect size in primary insomnia without circadian disruption is correspondingly more modest.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.